替加环素和对照药物（2014-2016 年）对世界卫生组织“重点病原体”的体外活性及 2004-2016 年抗菌药物耐药性的纵向评估：来自 T.E.S.T.研究的报告。
In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
机构信息
Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Goldenfelsstrasse 19-21, 50935 Cologne, Germany.
Clinical Microbiology, Royal University and the Saskatoon Health Region, Departments of Pathology and Laboratory Medicine, Microbiology and Immunology, and Ophthalmology, University of Saskatchewan, Saskatoon, Canada S7N 0W8.
出版信息
Int J Antimicrob Agents. 2018 Oct;52(4):474-484. doi: 10.1016/j.ijantimicag.2018.07.003. Epub 2018 Aug 21.
We report contemporary (2014-2016) Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) global data on activity of tigecycline and comparators against WHO 'priority pathogens', and global trends (2004-2016) in antimicrobial resistance. MICs were determined using CLSI broth microdilution methodology. Antimicrobial resistance was determined using CLSI breakpoints (FDA breakpoints for tigecycline). Data are reported for Africa, Asia, Europe, North America and South America. From 2014-2016, Africa, Asia and South America reported highest resistance rates among Acinetobacter baumannii; North America lowest (all antimicrobials tested). The tigecycline MIC against A. baumannii was 2 mg/L in all regions except South America (1 mg/L). Among Enterobacteriaceae, meropenem resistance was low and tigecycline resistance was ≤1.3% in all regions (Escherichia coli, 0.0-0.3%; Klebsiella pneumoniae 0.0-1.3%; Enterobacter spp. 0.5-1.1%; Serratia marcescens 0.0-1.3%). Ceftriaxone resistance among E. coli ranged from 14.5% (North America) to 54.7% (Asia), and among K. pneumoniae from 9.1% (North America) to 54.0% (South America). North America reported highest rates of vancomycin-resistant Enterococcus faecium (64.6%); Europe lowest (17.7%). The tigecycline MIC against methicillin-resistant Staphylococcus aureus (MRSA) ranged from 0.12 mg/L (Africa and North America) to 0.5 mg/L (Asia). From 2004-2016, carbapenem resistance increased among A. baumannii (all regions), reaching 92.3% in Africa and 85.7% in South America (2016). Rates of ceftriaxone-resistant E. coli increased in all regions except Asia. Ceftriaxone resistance in K. pneumoniae increased in Europe. Rates of vancomycin-resistant E. faecium and MRSA were highest in North America and South America (and Asia for MRSA); lowest in Europe.
我们报告了当代（2014-2016 年）替加环素评估和监测试验（T.E.S.T.）全球数据，这些数据涉及替加环素和对照药物对世界卫生组织“优先病原体”的活性，以及全球范围内（2004-2016 年）的抗微生物药物耐药性趋势。微量肉汤稀释法测定 MIC。抗微生物药物耐药性测定采用 CLSI 折点（替加环素的 FDA 折点）。数据来自非洲、亚洲、欧洲、北美洲和南美洲。2014-2016 年，非洲、亚洲和南美洲报告了鲍曼不动杆菌的最高耐药率；北美洲最低（所有测试的抗菌药物）。替加环素对鲍曼不动杆菌的 MIC 除南美洲为 1mg/L 外，其他地区均为 2mg/L。在肠杆菌科中，美罗培南耐药率较低，替加环素耐药率在所有地区均≤1.3%（大肠埃希菌，0.0-0.3%；肺炎克雷伯菌，0.0-1.3%；肠杆菌属，0.5-1.1%；粘质沙雷氏菌，0.0-1.3%）。大肠埃希菌中头孢曲松耐药率范围为 14.5%（北美洲）至 54.7%（亚洲），肺炎克雷伯菌中头孢曲松耐药率范围为 9.1%（北美洲）至 54.0%（南美洲）。北美洲报告的万古霉素耐药粪肠球菌（VRE）发生率最高（64.6%）；欧洲最低（17.7%）。替加环素对耐甲氧西林金黄色葡萄球菌（MRSA）的 MIC 范围为 0.12mg/L（非洲和北美洲）至 0.5mg/L（亚洲）。2004-2016 年，鲍曼不动杆菌的碳青霉烯类耐药性（所有地区）增加，非洲达 92.3%，南美洲达 85.7%（2016 年）。除亚洲外，所有地区的头孢曲松耐药大肠埃希菌发生率均增加。欧洲的肺炎克雷伯菌对头孢曲松的耐药性增加。万古霉素耐药粪肠球菌和耐甲氧西林金黄色葡萄球菌的发生率在北美洲和南美洲最高（亚洲也为耐甲氧西林金黄色葡萄球菌）；在欧洲最低。
Zotero 插件